{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:40:09Z","timestamp":1751406009918,"version":"3.41.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Clinical guidelines recommend the use of statins to reduce portal pressure and alleviate portal hypertension (PH). However, there is a lack of population-level studies on the use of non-statin Low-Density Lipoprotein Cholesterol (LDL-c) reduction agents for the treatment of PH. This study utilized a novel method, Mendelian Randomization (MR) analysis, to investigate the impact of commonly used LDL-c-lowering medications on PH. Instrumental variables (IVs) for eight lipid-lowering drug-related genes were extracted from three large-scale LDL-c databases of Genome-Wide Association Studies (GWAS), followed by MR analysis. The MR results indicated that, compared to normal individuals, lower expression of CETP and NPC1L1 in whole blood (result of meta-analysis: CETP [OR: 0.322, 95%CI:0.130\u20130.795, <jats:italic>P<\/jats:italic>\u2009=\u20091.396e-02], NPC1L1 [OR: 0.057, 95%CI: 0.022\u20130.146, <jats:italic>P<\/jats:italic>\u2009=\u20092.670e-09]) is associated with reduced portal pressure. The IVs of target genes were subjected to MR analysis with coronary atherosclerosis (CAD) as a positive control, confirming that the IVs can effectively substitute for the biological function of the target gene, thereby further enhancing the reliability of the results. Subsequently, Summary-based Mendelian Randomization (SMR) analysis was conducted by using expression quantitative trait loci (eQTL) data to validate the results of the MR analysis. The SMR results suggested that only NPC1L1 is associated with PH (OR: 0.648, 95%CI: 0.472\u20130.891, <jats:italic>P<\/jats:italic>\n            <jats:sub>\n              <jats:italic>SMR<\/jats:italic>\n            <\/jats:sub> = 7.502e-3, <jats:italic>P<\/jats:italic>\n            <jats:sub>\n              <jats:italic>HEIDI<\/jats:italic>\n            <\/jats:sub> = 0.747) from genetic correlation. Additionally, mediation analysis indicates that the therapeutic effect of NPC1L1 inhibitors on PH is partially mediated by tissue factor (mediating effect accounted for 18.52%, and the <jats:italic>P<\/jats:italic> value was 0.01). Phenome-Wide MR indicated that NPC1L1 inhibitors may be associated with 23 diseases or symptoms. In addition, NPC1L1 had genetic correlation between and alkaline phosphatase as well as total bilirubin, but no genetic correlation with alanine aminotransferase, aspartate aminotransferase, direct bilirubin, or gamma glutamyltransferase. In conclusion, this study systematically analyzed the genetic correlation between lipid-lowering drug targets and PH. From a genetic correlation perspective, we revealed that the potential therapeutic effect of NPC1L1 on PH may not be mediated through the reduction of LDL-c but rather through the modulation of tissue factors. Additionally, the potential side effects associated with NPC1L1 inhibition also were explored.<\/jats:p>","DOI":"10.1038\/s41598-025-08153-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:10:03Z","timestamp":1751404203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic association analysis between LDL-c lowering drugs and portal hypertension using Mendelian randomization analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-7794","authenticated-orcid":false,"given":"Qing-Ao","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0907-1010","authenticated-orcid":false,"given":"Xiao-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4440-5884","authenticated-orcid":false,"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-9701","authenticated-orcid":false,"given":"Xiao-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"8153_CR1","doi-asserted-by":"crossref","unstructured":"1. Gines, P. et al. Liver cirrhosis. Lancet 398, 1359\u20131376, doi:10.1016\/S0140-6736(21)01374-X (2021).","DOI":"10.1016\/S0140-6736(21)01374-X"},{"key":"8153_CR2","doi-asserted-by":"crossref","unstructured":"2. de Franchis, R. et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 76, 959\u2013974, doi:10.1016\/j.jhep.2021.12.022 (2022).","DOI":"10.1007\/978-3-031-08552-9"},{"key":"8153_CR3","doi-asserted-by":"crossref","unstructured":"3. Airola, C. et al. Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications. Cells 12, doi:10.3390\/cells12131712 (2023).","DOI":"10.3390\/cells12131712"},{"key":"8153_CR4","doi-asserted-by":"crossref","unstructured":"4. Cerini, F. et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol 64, 834\u2013842, doi:10.1016\/j.jhep.2015.12.003 (2016).","DOI":"10.1016\/j.jhep.2015.12.003"},{"key":"8153_CR5","doi-asserted-by":"crossref","unstructured":"5. Bordbar, M. et al. Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. Thromb J 19, 45, doi:10.1186\/s12959-021-00299-2 (2021).","DOI":"10.1186\/s12959-021-00299-2"},{"key":"8153_CR6","doi-asserted-by":"crossref","unstructured":"6. Takada, T. et al. NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. Sci Transl Med 7, 275ra223, doi:10.1126\/scitranslmed.3010329 (2015).","DOI":"10.1126\/scitranslmed.3010329"},{"key":"8153_CR7","doi-asserted-by":"crossref","unstructured":"7. Pollo-Flores, P. et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis 47, 957\u2013963, doi:10.1016\/j.dld.2015.07.156 (2015).","DOI":"10.1016\/j.dld.2015.07.156"},{"key":"8153_CR8","doi-asserted-by":"crossref","unstructured":"8. Bishnu, S. et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol 30, 54\u201359, doi:10.1097\/MEG.0000000000001006 (2018).","DOI":"10.1097\/MEG.0000000000001006"},{"key":"8153_CR9","doi-asserted-by":"crossref","unstructured":"9. Kronborg, T. M. et al. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatology Communications 7, doi:10.1097\/hc9.0000000000000332 (2023).","DOI":"10.1097\/HC9.0000000000000332"},{"key":"8153_CR10","doi-asserted-by":"crossref","unstructured":"10. Sharpton, S. R. & Loomba, R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology 78, 1896\u20131906, doi:10.1097\/HEP.0000000000000278 (2023).","DOI":"10.1097\/HEP.0000000000000278"},{"key":"8153_CR11","doi-asserted-by":"crossref","unstructured":"11. Kjaergaard, A. D., Smith, G. D. & Stewart, P. Mendelian Randomization Studies in Endocrinology: Raising the Quality Bar for Submissions and Publications in The Journal of Clinical Endocrinology & Metabolism. J Clin Endocrinol Metab 109, 1\u20133, doi:10.1210\/clinem\/dgad569 (2023).","DOI":"10.1210\/clinem\/dgad569"},{"key":"8153_CR12","doi-asserted-by":"crossref","unstructured":"12. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601, doi:10.1136\/bmj.k601 (2018).","DOI":"10.1136\/bmj.k601"},{"key":"8153_CR13","doi-asserted-by":"crossref","unstructured":"13. Skrivankova, V. W. et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326, 1614\u20131621, doi:10.1001\/jama.2021.18236 (2021).","DOI":"10.1001\/jama.2021.18236"},{"key":"8153_CR14","doi-asserted-by":"crossref","unstructured":"14. Cai, G., Liu, J., Cai, M. & Shao, L. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study. Lipids in Health and Disease 23, doi:10.1186\/s12944-024-02218-6 (2024).","DOI":"10.1186\/s12944-024-02218-6"},{"key":"8153_CR15","doi-asserted-by":"crossref","unstructured":"15. Ridker, P. M. LDL cholesterol: controversies and future therapeutic directions. Lancet 384, 607\u2013617, doi:10.1016\/S0140-6736(14)61009-6 (2014).","DOI":"10.1016\/S0140-6736(14)61009-6"},{"key":"8153_CR16","doi-asserted-by":"crossref","unstructured":"16. Li, Z. et al. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. eBioMedicine 90, doi:10.1016\/j.ebiom.2023.104543 (2023).","DOI":"10.1016\/j.ebiom.2023.104543"},{"key":"8153_CR17","doi-asserted-by":"crossref","unstructured":"17. Bi, Y., Zhu, Y., Tang, S. & Huang, Y. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study. The Journal of Headache and Pain 24, doi:10.1186\/s10194-023-01633-x (2023).","DOI":"10.1186\/s10194-023-01633-x"},{"key":"8153_CR18","doi-asserted-by":"crossref","unstructured":"18. Karczewski, K. J. et al. Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and resolution into ancestry-enriched effects. medRxiv, doi:10.1101\/2024.03.13.24303864 (2024).","DOI":"10.1101\/2024.03.13.24303864"},{"key":"8153_CR19","doi-asserted-by":"crossref","unstructured":"19. Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675\u2013679, doi:10.1038\/s41586-021-04064-3 (2021).","DOI":"10.1038\/s41586-021-04064-3"},{"key":"8153_CR20","doi-asserted-by":"crossref","unstructured":"20. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45, 1274\u20131283, doi:10.1038\/ng.2797 (2013).","DOI":"10.1038\/ng.2797"},{"key":"8153_CR21","doi-asserted-by":"crossref","unstructured":"21. Vosa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet 53, 1300\u20131310, doi:10.1038\/s41588-021-00913-z (2021).","DOI":"10.1038\/s41588-021-00913-z"},{"key":"8153_CR22","doi-asserted-by":"crossref","unstructured":"22. Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet 13, e1006706, doi:10.1371\/journal.pgen.1006706 (2017).","DOI":"10.1371\/journal.pgen.1006706"},{"key":"8153_CR23","doi-asserted-by":"crossref","unstructured":"23. Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun 8, 14357, doi:10.1038\/ncomms14357 (2017).","DOI":"10.1038\/ncomms15345"},{"key":"8153_CR24","doi-asserted-by":"crossref","unstructured":"24. Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73\u201379, doi:10.1038\/s41586-018-0175-2 (2018).","DOI":"10.1038\/s41586-018-0175-2"},{"key":"8153_CR25","doi-asserted-by":"crossref","unstructured":"25. Fairley, S., Lowy-Gallego, E., Perry, E. & Flicek, P. The International Genome Sample Resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res 48, D941-D947, doi:10.1093\/nar\/gkz836 (2020).","DOI":"10.1093\/nar\/gkz836"},{"key":"8153_CR26","doi-asserted-by":"crossref","unstructured":"26. Gao, X. et al. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study. Eur J Prev Cardiol 31, 1132\u20131140, doi:10.1093\/eurjpc\/zwae044 (2024).","DOI":"10.1093\/eurjpc\/zwae044"},{"key":"8153_CR27","doi-asserted-by":"crossref","unstructured":"27. Zhao, S. S., Yiu, Z. Z. N., Barton, A. & Bowes, J. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. JAMA Dermatol 159, 275\u2013280, doi:10.1001\/jamadermatol.2022.6051 (2023).","DOI":"10.1001\/jamadermatol.2022.6051"},{"key":"8153_CR28","doi-asserted-by":"crossref","unstructured":"28. Yu, K. et al. Assessment of bidirectional relationships between brain imaging-derived phenotypes and stroke: a Mendelian randomization study. BMC Med 21, 271, doi:10.1186\/s12916-023-02982-9 (2023).","DOI":"10.1186\/s12916-023-02982-9"},{"key":"8153_CR29","doi-asserted-by":"crossref","unstructured":"29. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37, 658\u2013665, doi:10.1002\/gepi.21758 (2013).","DOI":"10.1002\/gepi.21758"},{"key":"8153_CR30","doi-asserted-by":"crossref","unstructured":"30. Zhao, J. et al. Bayesian weighted Mendelian randomization for causal inference based on summary statistics. Bioinformatics 36, 1501\u20131508, doi:10.1093\/bioinformatics\/btz749 (2020).","DOI":"10.1093\/bioinformatics\/btz749"},{"key":"8153_CR31","doi-asserted-by":"crossref","unstructured":"31. Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. Am J Hum Genet 108, 1251\u20131269, doi:10.1016\/j.ajhg.2021.05.014 (2021).","DOI":"10.1016\/j.ajhg.2021.05.014"},{"key":"8153_CR32","doi-asserted-by":"crossref","unstructured":"32. Chen, X. et al. Depression and prostate cancer risk: A Mendelian randomization study. Cancer Med 9, 9160\u20139167, doi:10.1002\/cam4.3493 (2020).","DOI":"10.1002\/cam4.3493"},{"key":"8153_CR33","doi-asserted-by":"crossref","unstructured":"33. Williams, S. M. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLoS Genetics 10, doi:10.1371\/journal.pgen.1004383 (2014).","DOI":"10.1371\/journal.pgen.1004383"},{"key":"8153_CR34","doi-asserted-by":"crossref","unstructured":"34. Luo, S. et al. Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK Biobank. Lancet Healthy Longev 4, e337-e344, doi:10.1016\/S2666-7568(23)00085-5 (2023).","DOI":"10.1016\/S2666-7568(23)00085-5"},{"key":"8153_CR35","doi-asserted-by":"crossref","unstructured":"35. Sun, J. et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med 15, 75, doi:10.1186\/s13073-023-01229-9 (2023).","DOI":"10.1186\/s13073-023-01229-9"},{"key":"8153_CR36","doi-asserted-by":"crossref","unstructured":"36. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 48, 481\u2013487, doi:10.1038\/ng.3538 (2016).","DOI":"10.1038\/ng.3538"},{"key":"8153_CR37","doi-asserted-by":"crossref","unstructured":"37. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet 50, 1335\u20131341, doi:10.1038\/s41588-018-0184-y (2018).","DOI":"10.1038\/s41588-018-0184-y"},{"key":"8153_CR38","doi-asserted-by":"crossref","unstructured":"38. Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50, 693\u2013698, doi:10.1038\/s41588-018-0099-7 (2018).","DOI":"10.1038\/s41588-018-0099-7"},{"key":"8153_CR39","doi-asserted-by":"crossref","unstructured":"39. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44, 512\u2013525, doi:10.1093\/ije\/dyv080 (2015).","DOI":"10.1093\/ije\/dyv080"},{"key":"8153_CR40","doi-asserted-by":"crossref","unstructured":"40. Pierce, B. L., Ahsan, H. & Vanderweele, T. J. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40, 740\u2013752, doi:10.1093\/ije\/dyq151 (2011).","DOI":"10.1093\/ije\/dyq151"},{"key":"8153_CR41","doi-asserted-by":"crossref","unstructured":"41. Vilaseca, M. et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology 65, 2031\u20132044, doi:10.1002\/hep.29084 (2017).","DOI":"10.1002\/hep.29084"},{"key":"8153_CR42","doi-asserted-by":"crossref","unstructured":"42. Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651\u20131658, doi:10.1053\/j.gastro.2009.01.043 (2009).","DOI":"10.1053\/j.gastro.2009.01.043"},{"key":"8153_CR43","doi-asserted-by":"crossref","unstructured":"43. Scheiner, B. et al. Factor VIII\/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol 76, 1090\u20131099, doi:10.1016\/j.jhep.2021.12.038 (2022).","DOI":"10.1016\/j.jhep.2021.12.038"},{"key":"8153_CR44","doi-asserted-by":"crossref","unstructured":"44. Elkrief, L. et al. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies. Lancet Gastroenterol Hepatol 9, 859\u2013883, doi:10.1016\/S2468-1253(24)00155-9 (2024).","DOI":"10.1016\/S2468-1253(24)00155-9"},{"key":"8153_CR45","doi-asserted-by":"crossref","unstructured":"45. Turon, F. et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol 75, 1367\u20131376, doi:10.1016\/j.jhep.2021.07.020 (2021).","DOI":"10.1016\/j.jhep.2021.07.020"},{"key":"8153_CR46","doi-asserted-by":"crossref","unstructured":"46. Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 4851\u20134853, doi:10.1093\/bioinformatics\/btz469 (2019).","DOI":"10.1093\/bioinformatics\/btz469"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08153-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:10:23Z","timestamp":1751404223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08153-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08153-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22238"}}